Background: Dizziness is a common complaint, and the symptom often persists, together with additional complaints. A treatment combining Vestibular Rehabilitation (VR) and Cognitive Behaviour Therapy (CBT) is suggested. However, further research is necessary to evaluate the efficacy of such an intervention. The objective of this paper is to present the design of a randomised controlled trial aiming at evaluating the efficacy of an integrated treatment of VR and CBT on dizziness, physical function, psychological complaints and quality of life in persons with persistent dizziness.
Background
Vertigo and/or dizziness are amongst the most frequent symptoms reported in outpatient practices [1] , with a lifetime prevalence reported in approximately 30% [2] . Dizziness can present for a variety of reasons, many initiated through vestibular disease; however, it is not always possible to identify a specific cause or diagnosis [3] .
Psychological factors, such as anxiety, seem to be closely related to the prevalence of dizziness [4, 5] , and it is likely that biological and psychological factors interact, maintaining the vestibular symptoms as well as the anxiety [4, 6] . In chronic dizziness it is common to avoid movements, activities and social settings that may provoke symptoms and discomfort [7] . This fear of provoking dizziness and discomfort may also lead to an 'en bloc' movement pattern. Some studies on persons with persistent dizziness have also reported musculoskeletal symptoms [8] like, for instance, postural malalignments [9] and musculoskeletal pain [10] , particularly in the neck-shoulder area [10] [11] [12] . Long-term consequences of such avoidance strategies may hamper compensation strategies and functional improvements, eventually leading to occupational disability [13] .
Vestibular Rehabilitation (VR) is an exercise-based treatment approach for dizziness, primarily directed towards reducing vestibular symptoms (not musculoskeletal aberrations), with moderate to strong evidence of VR for conditions of unilateral vestibular hypofunction [14] . A recent review has indicated that VR may also be used in other conditions such as vestibular disorders of central origin [15] . Since musculoskeletal symptoms are not specifically targeted in VR interventions, one longitudinal study (no control group) incorporated bodyawareness therapy [16] into VR, with positive effects on musculoskeletal aberrations, such as improved bodily flexibility and balance during ambulation, as well as improved perception of dizziness [17, 18] .
As mentioned, VR treatment is developed as an exercisebased treatment; however, it also contains some cognitive elements, such as graded exposure (habituation), that also facilitates cognitive restructuring (e.g. reduce avoidance behaviour) [7, 19] . A recent randomised controlled trial (RCT), providing just three sessions of Cognitive Behaviour Therapy (CBT) for panic anxiety, found reduced dizziness, handicap and use of safety behaviours in persons with chronic subjective dizziness [20] . Furthermore, the positive changes were maintained at 6-month follow-up [21] , but the outcomes only focussed on psychological complaints, and no objective outcomes were assessed.
As both VR and CBT have shown positive effects on persons with dizziness, the combination of VR and CBT seems to be an appropriate treatment approach for persistent dizziness, and a few studies have investigated this combination [22] [23] [24] [25] . The effects of the combined VR and CBT treatments are reported to be reduced dizziness-related handicap [23] [24] [25] , improved walking [23] , and reduced anxiety and depression [25] . A systematic review on psychotherapy in dizziness found a small and clinically relevant effect on dizziness, but no effect on anxiety and depression [26] . However, the included studies had small sample sizes (19 to 31 participants) [23] [24] [25] , no random allocation [25] , no standardised CBT treatment manual [25] , and improvements found in the short-term were not maintained as long-term effects [22] . Further, as none of the combined treatments included a focus on musculoskeletal complaints, there is a need to further develop the treatment combining VR and CBT, also targeting the musculoskeletal aspects, and afterward the effects of the programme must be tested in a RCT. A recent feasibility study integrating VR and CBT with an additional focus on musculoskeletal effects showed that such a treatment approach was feasible and safe [27] . Therefore, this treatment is now ready to be evaluated in a RCT.
Study objectives
The aim of the RCT is to evaluate the short-(6 months) and long-term (12 months) efficacy of an integrated treatment of VR and CBT in persons with persistent dizziness. It is hypothesised that persons receiving the additional Vestibular Rehabilitation and Cognitive Behaviour Therapy (VR-CBT) programme will show superior reduction in self-reported dizziness-related handicap in addition to increased preferred gait velocity compared with persons receiving Brief Intervention Vestibular Rehabilitation (BI-VR) alone.
Methods/design

Study design
The study is a prospective, assessor-blinded, block-RCT, with a parallel-group design, with a 6-and 12-month follow-up. The protocol conforms with the recommendations from the EQUATOR network [28] , using the Standard Protocol Items: Recommendations for Interventional Trails (SPIRIT) Checklist and the Consolidated Standard of Reporting Trials (CONSORT) guidelines when reporting the results [29, 30] . The SPIRIT Checklist is available in Additional file 1.
Settings and location
Participants will be recruited through general practitioners, physiotherapists, ear, nose and throat specialists, and information through newspapers and social media. Participants will be recruited from the region in and around Bergen, Norway. Blinded baseline and follow-up testing and the one-session VR intervention (BI-VR) will be conducted at the Western Norway University of Applied Sciences (HVL). Group treatment (VR-CBT) will be offered at HVL, as well as at selected physiotherapy clinics in Bergen. The group treatment will be led by physiotherapists trained in the treatment protocol (please see below).
Participants
Eligible participants must meet all the following inclusion criteria: be of working age (18-70 years) with acute onset of dizziness and with symptoms lasting at least 3 months, and the dizziness has to be triggered/worsened by head movements, Participants will be excluded if they meet one or more of the following exclusion criteria: self-reported non-vestibular reason for dizziness (e.g. neurological conditions) or fluctuating vestibular diseases (e.g. Ménière's disease); scheduled for treatment of/have had treatment for benign paroxysmal positional vertigo (BPPV) within 1 month; fast head movements are contraindicated (e.g. whiplash-associated injuries, osteoporosis of the neck); presentation of severe/terminal pathology (cancer, psychiatric diagnosis); participation in group therapy for dizziness within the past year; inadequate Norwegian language proficiency (verbal and written); or unable to attend test and treatment locations.
Procedure
Eligible participants will initially be screened by a telephone interview followed by further screening at HVL. Participants fulfilling the inclusion and exclusion criteria who are willing to participate will be asked to sign an informed consent (Additional file 2, in Norwegian). The first meeting comprises screening by the assessors, signing of informed consent, and baseline testing. This is scheduled to last 2 h. During baseline testing the included participants will complete physical tests and questionnaires. Following baseline testing the participants attend a 1-h treatment session (BI-VR), and afterwards randomisation to either the intervention group or the control group. Follow-up testing is scheduled 6 and 12 months after inclusion ( Table 1) comprising online or paper versions of the questionnaires (completed separately from testing) and objective outcomes. Both follow-up tests are scheduled to last up to 1 h.
Interventions
Brief Intervention Vestibular Rehabilitation
All the participants receive BI-VR, a single-session treatment based on elements from traditional VR [31, 32] , but adapted to a single session in line with a brief intervention model developed for patients with low back pain [33] . The purpose of the treatment is to give the participant the understanding that movement is the key factor in improving symptoms and that dizziness is rarely related to serious illness. BI-VR comprises examination, information regarding the vestibular system, what causes dizziness, advice related to specific findings, and supervision in selected, standardised VR exercises. All participants are encouraged to stay active, and provoke dizziness in line with established recommendations [14, 34] .
Control group
Participants allocated to BI-VR only will be encouraged to do the prescribed exercises on their own. The BI-VR physiotherapist will call twice during a 4-month period, to encourage compliance with the home exercises and answer questions that may arise.
Intervention group Vestibular Rehabilitation and Cognitive Behavioural Therapy
Participants in the intervention group will be invited to attend an additional structured group-treatment programme integrating Vestibular Rehabilitation and Cognitive Behaviour Therapy (VR-CBT). The VR-CBT manual was developed through collaboration between researchers, physiotherapists and clinical psychologists. The treatment offers eight weekly 2-h sessions with five to eight participants in each group, with the aim of addressing both the physical and psychological challenges of persistent dizziness. The CBT approach is based on previous findings indicating that treatment for panic disorders can also be efficacious for persons with chronic dizziness [20] . CBT focusses on the vicious cycle between somatic anxiety symptoms elicited by the 'fight or flight' response, the catastrophic misinterpretations of these and other bodily symptoms, and the resulting safety-seeking and avoidance behaviour [35] . The VR comprises habituation, gaze stability and balance exercises, with body awareness promoted throughout, in addition to guided relaxation [34, 36] . The exercises may be individually adapted by, for instance, adjustments in base of support, speed of movement, and environmental conditions. All sessions will have elements of both VR and CBT; however, the first three sessions mostly emphasise CBT, while the subsequent five sessions mostly emphasise VR. This set-up allows the participants to practise exercises in a safe environment, and provides opportunities to reflect on dizziness, safety and avoidance behaviours that may occur. Participants are further asked to carry out and register home exercises following the treatment sessions, and daily VR exercises are introduced from session 3 onwards. A brief description of the VR-CBT manual is presented in Table 2 .
Physiotherapists
One physiotherapist experienced in VR, and trained in the BI-VR protocol, will run all BI-VR sessions. Six physiotherapists delivering the VR-CBT treatment will attend a competency course to before leading the treatment. The competency course contains the principles of VR-CBT, the elements of the treatment manual, and training of practical skills related to the manual, as described in the feasibility study [27] . After each of the first two treatment sessions a clinical psychologist and the principal investigator will be available for support and guidance, without unblinding participant allocation.
Data collection and follow-up
Three assessors (principal investigator, project lead and one research assistant) are involved in collecting informed consent, and blinded data collection at baseline and follow-up, adhering to the standardised test protocol. In addition, the assessors will practise together before and during data collection, in order to unify performance and interpretation of the outcome measures. The principal investigator will perform the majority of the data collection.
Personal information related to the participants will be stored on a secure server only accessible to the researchers involved in the research projects. Outcomes collected on paper will be registered into a secure file and placed on the same server, and paper copies will be kept in a locked cupboard only accessible by the principle investigator. After completion of the project all paper copies will be destroyed, and the dataset will be anonymised. Table 3 describes the outcomes that will be collected at the various stages in the study.
Outcome measures
Primary outcome measures
The primary outcome measures are the Dizziness Handicap Inventory (DHI) and preferred gait velocity. The DHI is a questionnaire developed in order to assess the impact of dizziness on quality of life (QoL) [37] . It is translated into Norwegian and has shown satisfactory test-retest reliability [39] . Preferred gait velocity is assessed using the 6- m timed gait test, with one additional metre at each end allowing acceleration and deceleration [41] . The test has been found to be reliable in healthy adults [63] , as well as in persons with vestibular disorders [41] .
Secondary outcome measures
The secondary outcomes include dizziness severity, psychological complaints, fatigue, subjective health complaints, standing balance, walking, strength, flexibility and general QOL. The patient-reported outcomes is used to evaluate dizziness severity using the Norwegian version [43] of the Vertigo Symptom Scale short form (VSS) [42] . In addition, the Hospital Anxiety and Depression Questionnaire (HADS) [48] , the Body Sensations Questionnaire (BSQ) [45] , the Agoraphobic Cognition Questionnaire (ACQ) [45] , the Mobility Inventory of Agoraphobia-Alone (MIA) [46] , and an adapted version of the Panic Attack Scale (PAS) [47] describes levels of anxiety, depression, panicrelated symptoms and avoidance behaviour. Further, fatigue is assessed using the Chalder's Fatigue Questionnaire (CFQ) [54] , while the Subjective Health Complaints (SHC) inventory reports incidents and extent of subjective somatic and psychological complaints [64] . The Patient Specific Functional Scale (PSFS) assesses perceived functional change [56] , while information regarding QOL is gathered using the EuroQol five-dimension, five-level health survey (EQ-5D-5 L) [65] .
Secondary objective measures include standing balance (sway measured during the four conditions in the modified clinical test for sensory interaction and balance (mCTSIB)) [66] using balance trainer BTG4 (HUR health, Kokkola, Norway), walking (fast velocity and with dual task [67] ), visual acuity (Clinical Dynamic Visual Acuity Test (CDVA) [59] ) and grip strength [68] . Musculoskeletal aberrations are registered using four elements from the 25 items, each item has 3 alternative scores 0 (no), 2 (sometimes) and 4 (yes) giving a score range of 0-100 DHI points [37] . Higher scores indicate greater perceived disability; 0-30; mild, 31-60; moderate, 61-100; severe [38] Cut-off 29 points, MIC 11 DHI points, ICC 1,1 0.90 [39] .
Preferred gait velocity (m/s) Participants walked at normal pace, down an 8-m pathway, timed in the middle 6 m. It was timed using a stopwatch from when the first foot passed the start point to when the last foot passed the stop point. Mean velocity over two trials were calculated Substantial meaningful change 0.1 m/s [40] , ICC (3.1): 0.88 (CI 0.81-0.98) [41] Secondary outcomes/patient-reported outcomes
The shortened version of the Vertigo Symptom Scale (VSS) 15 items, each scoring from 0 (never) to 4 (very often) giving a score range of 0-60. Higher scores indicate greater symptom severity [42] . Severe dizziness ≥ 12 [42] Norwegian version cut-off, 6.5 points [43] . Clinically significant change in original version ≥ 3 points [44] . ICC Norwegian version, 0.89 [43] Agoraphobic Cognitions Questionnaire (ACQ) 14 items, each rated on a scale ranging from 1 (thought never occurs when I am nervous) to 5 (thought always occurs when I am nervous) [45] . Measures fear of fear. The mean score is reported, and higher scores imply greater levels of fear Cronbach's alpha for outpatients with agoraphobia, 0.80 [45] Body Sensation Questionnaire (BSC) 18 items, each with a score range from 1 (not at all frightened by the sensations) to 5 (extremely frightened by this sensation). The mean score reported, and higher scores implies greater fear of somatic sensations [45] Cronbach's alpha for outpatients with agoraphobia, 0.87 [45] Mobility Inventory of Agoraphobia-Alone (MIA) 27 items, each rated from 1 (never avoids) to 5 (always avoids). The mean score is reported and, and higher scores indicate greater avoidance behaviour Cronbach's alpha in agoraphobia, 0.96 [46] Adapted Panic Attack Scale
• Attack frequency Measures frequency of distress related to sudden onsets of episodes with 4 or more strong sensations of dizziness and dizziness related symptoms on a 5-point scale ranging from 0 (no attacks) to 4 (one or more attacks per day). Adapted from the Panic Attack Scale [47] • Attack severity Severity rating of the degree of distress related to the episodes described above. Numeric rating scale with a score range 0-8. Higher scores indicates increased symptom-related distress/disability. Adapted from the Panic Attack Scale [47] Hospital Anxiety and Depression Scale (HADS) 14 items, each rated from 0 (not present) to 3 (considerable), giving a score range of 0-42 points [48] . Higher scores indicates greater psychological distress Cut-off 12 points, Cronbach's alpha, 0.88. [49] EQ-5D-5 L Generic instrument describing and valuing health [50] .
• EQ-5D-5 L Five dimensions, each rated from 1 to 5. Higher scores indicate increased health problems [51] • EQ-5D-5 L Vas Score range 0-100%. Chalder's Fatigue Questionnaire (CFQ) 13 items. The first 11 items are scored from 0 (better than usual) to 3 (much worse than usual), giving a score range of 0-33. The last 2 items rate duration and constancy of fatigue [54] . Higher scores indicating more fatigued Cronbach's alpha in Norwegian population, 0.86 [55] Patient Specific Functional Scale (PSFS)
Registers up to 3 activities that participants find difficult. In addition, the level of difficulty is rated on an 11-point scale [56] , where 0 maximum difficulty and 10 is no difficulty Reliability established in various musculoskeletal problems (ICC 0.76-0.97) [57] MCID in various musculoskeletal problems, 0.99-2.5 [57] Kristiansen et al. Trials (2019) 20:575
Global Physiotherapy Examination (GPE) [17] and headmovement-induced dizziness [41] measured using the numeric rating scale (HmDizz). The Patient Global Impression of Change questionnaire (PGIC) [58] is used to evaluate perceived improvement at follow-up testing at 6 and 12 months.
Demographic data and other measurements
In addition to the outcomes, information regarding gender, age, work status, medication and activity level will be gathered. The VR-CBT physiotherapists will register attendance to all sessions and reasons for absence and collect the home-exercise registrations. Satisfactory compliance to VR-CBT will be defined as minimum 75% attendance to VR-CBT sessions (six out of eight sessions), and minimum 80% completion of the exercise diary for home exercises, where 100% completion is defined by reporting exercises and following a walking programme five times per week. Satisfactory compliance in the control group will be defined as completion of at least one telephone call with the BI-VR physiotherapist.
Sample size and power considerations
The study is designed as a RCT comparing two groups (BI-VR, and BI-VR with VR-CBT). To obtain a clinically important group difference in DHI of 11 points [39] with a significance level of 0.05 and a power of 80%, 47 participants will be required per group. To obtain a clinically important change in preferred gait velocity of 0.1 m/ s [69] with a significance level of 0.05 and a power of 80%, 36 participants will be required in each group. In order to ensure power of both primary outcomes at least 47 participants are selected as the basis for the sample size needed in the study. The final sample size is set at 125 participants, allowing for an approximately 35% drop-out, based on drop-outs in the feasibility study [27] and in previous studies [18, 20, 70, 71] .
Randomisation and concealment of allocation
The participants are block-randomised in groups of 16, and randomly assigned to BI-VR followed by VR-CBT (intervention group) or BI-VR alone (control group). Group allocation is performed using a random number 1item, rated from 1 (very much improved) to 7 (very much worse), with a score of 4 indicating no change [58] Secondary outcomes/physical tests Dual-task walking Similar walking protocol as for preferred gait velocity, with an added task of counting backwards by 3 out loud, while walking. Each trial was timed and the numbers of miscounts were documented. Mean velocity, and mistakes over 2 trials calculated Fast gait velocity (m/s) Similar protocol to preferred gait velocity; however, participants were asked to walk as fast as possible
Clinical dynamic visual acuity (CDVA)
Evaluates gaze stability by assessing visual acuity using examiner-mediated head oscillations at 2 Hz relative to head being stationary
Cut-off ≥ 3 lines indicates potential vestibular hypofunction [59] . Reliability in bilateral peripheral hypofunction ICC (2.2): 0.94 [60] Head-movementinduced dizziness
Perceived dizziness reported using the Numeric Rating Scale (NRS) on 2 conditions: 1 while sitting stationary, and 1 after 1 min of active head oscillations at 1 Hz (following a metronome). Score range 0 (no dizziness) to 10 (as bad as it can be), with higher scores indicating higher perceived intensity of headmovement-induced dizziness. Difference between the two conditions will also be calculated generator and is presented on a folded paper, in a concealed envelope. The principle investigator is blinded from group allocations. The envelopes are stored in a locked cupboard only accessible to the BI-VR physiotherapist handing out the allocation envelopes. After group allocation the VR-CBT participants will be contacted by the project lead regarding the first VR-CBT appointment.
Blinding
The principal investigator and assessors are blinded from group allocation and not involved in the treatment of the participants. Blinding of group allocation for VR-CBT physiotherapists and participants is not possible. However, both groups are informed that the optimal treatment is not known, and the study hypothesis is not presented. In order to ensure blinding of assessors the participants are encouraged not to reveal their allocation during testing.
Statistical analysis plan
The efficacy analysis is assessment of the between-group differences in changes in DHI score and preferred gait velocity at 6-and 12-month follow-up. The analysis will use the intention-to-treat (ITT) principle, analysing all randomised participants independent of compliance and withdrawals. In the event of missing data two methods will be used. For missing single questions, the mean baseline value for the respected group will be assigned. If complete questionnaires or objective measures are missing a non-responder imputation will be used, including baseline data carried forward. Sensitivity analyses will be performed to study whether those who drop out differ from those who complete the required programme. An analysis of covariance (ANCOVA) will be used to analyse mean changes in continuous variables, and logistic regression for categorical variables. The model will include the respective dependent variable, in addition to fixed effects of group allocation, baseline value, age, gender and height.
The results will be expressed as a difference between the group means and 95% confidence intervals with associated p values. The main analyses will be conducted by a statistician not involved in the testing and blinded to group allocation. All data analysis will be performed according to a pre-established statistical analysis plan and interpreted according to a consensus document signed by all authors. All analyses will be performed using Statistical Package for Social Sciences (SPSS) (version 25, IBM, Armonk, NY, USA).
Interim analyses
Drop-out rates will be assessed in interim analyses to determine the potential need for adjustment in sample size in line with the power calculations.
Ethical considerations
Although participants may experience increased symptoms in the short term, it is not anticipated that participation will cause any serious adverse events or harms. A recent feasibility study [27] has confirmed that the intervention BI-VR and VR-CBT is feasible and safe for persons with persistent dizziness. If participants experience harm from the treatment delivered within the study, this will be registered, and the person will be directed for further assessment and follow-up care in accordance with the provisions that are customary within the national, public health care system. The study will follow the criteria and principles of the Declaration of Helsinki. It has been approved by the Regional Committee for Medical and Health Research Ethics (2014-00921) and is registered at www.clinicaltrials.gov (NCT02655575).
Discussion
In recent years there has been more focus on including cognitive approaches into the treatment of persistent dizziness [20, 72] . However, as previously mentioned there are only a few studies conducted on the effect of combining VR and CBT in persons with persistent dizziness [23] [24] [25] . All of the studies have scientific limitations as mentioned, categorising them as moderate quality. The promising result of the recent studies, and the lack of high-quality studies have shown the need for further studies on the efficacy of combining CBT and VR for participants with persistent dizziness.
The novelty of the current study is the integration of VR and CBT, with an additional focus on musculoskeletal complaints, as treatment for persons with persistent dizziness. The previous studies conducted CBT as supervised sessions (individually [25] or in small groups [23, 24] ) while VR exercises where administered as home exercises [24, 25] . The integration of the supervised VR-CBT sessions in the current RCT allows the participants to practise exercises in a safe environment supervised by physiotherapists, and the exercises may be adapted to meet the level of complaints and capacity in each participant.
One possible limitation in the study, as with all exercise trials, is the inability to blind physiotherapists and participants to treatment allocation. Thus, only the testers can be blinded to group allocation. Another possible limitation includes the specification of compliance criteria, which to our knowledge has not been done in this research area before, and there is no consensus regarding how much is sufficient. Also, a block-randomisation of 16 may be seen as a limitation as it may take time before the group number is reached. In addition, confounding factors like, for instance, age, gender, duration of complaints and psychological factors, may have an impact on primary and secondary outcomes. However, the randomised design is expected to distribute these variables equally between the allocation groups.
The strength of the current study is the inclusion of relevant reliable main outcomes with a sufficiently powered sample size. In addition, the study utilises standardised testing procedures, evaluating both short-and long-term efficacy. Another strength is the initial feasibility study conducted, showing that the test procedures and interventions were feasible and sage for the present population [27] . To our knowledge, the current RCT study is the largest study to date, combining VR and CBT to treat persons with persistent dizziness.
The aim of the current study is to evaluate the efficacy of BI-VR followed by VR-CBT, compared with BI-VR alone. If the treatment group improves more than the control group, the description of a standardised programme may help practitioners to treat persons with persistent dizziness. If there is no difference between the groups, it may indicate that persons with persistent dizziness may manage their complaints with minimal support from physiotherapists.
Trial status and publication plan
Recruitment of participants to the main study, applying version 2 (dated 30 January 2016) of the study protocol, started on 1 February 2016 and is expected to end by 1 May 2019. At the time of submission of this protocol (April 2019) the trial is ongoing and still recruiting. Currently, 106 participants have been included. When recruitment is finished the data will be analysed, interpreted and published regardless of positive, negative or inconclusive results. 
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